International study of Artificial Intelligence-based Diagnosis of Cardiomyopathy using Cardiac MRI
This study is testing the ability of artificial intelligence-based algorithms to look at cardiac MRI images to: i) decide what disease a patient has, and ii) predict if a patient will experience a major cardiac complication in the near future. The accuracy of these algorithms needs to be tested in different places and across different patient groups before it can be used in real world practice. This study aims to test the accuracy of these algorithms in an international setting
Interventional Endocrinology | NYU Langone Health
NYU Langone’s Thyroid Program offers patients radiofrequency ablation, nanosecond pulsed field ablation, alcohol ablation, and thyroid artery embolization.
Interventional Procedures for Hyperthyroidism | NYU Langone Health
NYU Langone doctors use thyroid radiofrequency ablation or nanosecond pulsed field ablation to treat thyroid nodules that cause hyperthyroidism.
Interventional Procedures for Thyroid Nodules & Cancers | NYU Langone Health
Doctors at NYU Langone’s Thyroid Program specialize perform minimally invasive interventional procedures to treat thyroid nodules and some thyroid cancers.
Interventional Radiology | NYU Langone Health
Interventional radiologists use imaging guidance to treat many conditions in a minimally invasive manner.
Interventional Radiology Conditions We Treat | NYU Langone Health
Interventional radiologists at NYU Langone use imaging guidance to treat many conditions in a minimally invasive manner.
Interventional Radiology Doctors | NYU Langone Health
Find a doctor at the Interventional Radiology at NYU Langone.
Interventional randomized double-blind parallel-group placebo-controlled multi-centre study to assess the efficacy safety and tolerability of Lu AF82422 in patients with Multiple System Atrophy
This is a phase II, interventional, randomized, double-blind, parallel-group, placebocontrolled, multi-centre study of the efficacy (slowing disease progression), safety, and tolerability of Lu AF82422 in patients with MSA.MSA is a progressive, fatal disorder characterized by autonomic failure and parkinsonismand/or cerebellar involvement. Neuropathologically, MSA is characterized by oligodendroglial inclusions of abnormally aggregated a-synuclein. No disease-modifying therapies are currently available; symptomatic treatment options are limited, and the therapeutic benefit of these therapies is often only transient. Thus, there is a critical unmet need for a treatment that can delay the progression in MSA. a-synuclein is considered a valid target for immunotherapies that aim to neutralize and/or clear toxic a-synuclein species, Lu AF82422 is a human IgG1 mAb that recognizes all major species of a-synuclein and is being developed as a treatment for delaying of disease progression in idiopathic PD and/or MSA.Nonclinical and clinical data of Lu AF82422 supports its potential as a safe and well tolerated treatment to reduce or inhibit seeding of pathological form(s) of a-synuclein, and potentially delay disease progression in MSA.
Interventional randomized double-blind placebo-controlled optional open-label extension trial of Lu AF82422 in participants with Multiple System Atrophy.
The purpose of this trial is to investigate whether Lu AF82422 is safe and effective in treating patients with multiple systematrophy (MSA). This trial will compare the effects of the trial drug, Lu AF82422, to placebo (inactive medication). Both the trial drug and placebo will be given as an infusion. Researchers use a placebo to see if a trial drug works better or is safer than not taking anything at all.
Interventional Therapy for Intraocular Melanoma | NYU Langone Health
NYU Langone doctors use interventional therapies to manage intraocular melanoma that has spread to the liver.